CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN

Authors:

Abstract
No abstract available
Funding Information
  • National Institute of Health (K25 AG043546, P30 AG028383, R01-AG044546, P01-AG003991, RF1AG053303, R01-AG035083, R21 AG050146)
  • Alzheimer's Disease Neuroimaging Initiative (ADNI)
  • National Institutes of Health (U01 AG024904)
  • Department of Defense (W81XWH-12-2-0012)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • AbbVie
  • Alzheimer's Association
  • Alzheimer's Drug Discovery Foundation
  • Araclon Biotech
  • BioClinica, Inc.
  • Biogen
  • Bristol-Myers Squibb Company
  • CereSpir, Inc.
  • Cogstate
  • Eisai Inc.
  • Elan Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • EuroImmun
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Fujirebio
  • GE Healthcare
  • IXICO Ltd.
  • Janssen Alzheimer Immunotherapy Research & Development, LLC
  • Johnson & Johnson Pharmaceutical Research & Development LLC
  • Lumosity
  • Lundbeck
  • Merck & Co., Inc.
  • Meso Scale Diagnostics, LLC
  • NeuroRx Research
  • Neurotrack Technologies
  • Novartis Pharmaceuticals Corporation
  • Pfizer Inc.
  • Piramal Imaging
  • Servier
  • Takeda Pharmaceutical Company
  • Transition Therapeutics
  • Canadian Institutes of Health Research
  • NIH (P30 AG010129, K01 AG030514)
  • Dana Foundation
  • National Cell Repository for AD (NCRAD) (U24 AG21886)
  • National Institute on Aging (AIG)

This publication has 46 references indexed in Scilit: